IHMA Completes the Globalization of its Two Laboratories with the Recent College of American Pathologists (CAP) Accreditation of IHMA Europe
Enhancing Support for Clinical Trials in Anti-Infective Drug Development and Global Surveillance Studies
SCHAUMBURG, Ill., March 06, 2018 (GLOBE NEWSWIRE) -- On 14th October 2017 IHMA Europe Sàrl, located in Monthey, Valais, Switzerland, was awarded accreditation by the College of American Pathologists (CAP). With this important development both IHMA facilities, located in the US and Europe, are now CAP accredited. These accreditations further advance IHMA's global commitment to the highest quality of central laboratory clinical microbiology services that are essential for providing timely and accurate results in support of anti-infective clinical trials and global surveillance studies on a worldwide basis.
IHMA Europe's Chief Executive Officer, Dr Stephen Hawser said, "CAP accreditation is a truly positive acknowledgement of the high quality of services IHMA Europe provides to the pharmaceutical and biotechnology industries to support antimicrobial development".
Jack Johnson, President and CEO of IHMA said, "It has been our desire to globalize the two laboratories to ensure our pharmaceutical and biotechnology clients, that all services provided by IHMA and IHMA Europe are exactly the same and meet the highest standards and quality found in our industry. The CAP accreditation provides that platform."
About IHMA, Inc. and IHMA Europe S à rl
IHMA is based in Schaumburg, IL USA and Monthey, Switzerland and has been a premier provider of antimicrobial drug development services over the past 25 years. Our laboratory facilities in both the US and Europe partner with clients around the world in the biotechnology, pharmaceutical, and diagnostic industries. IHMA is a leading, independent laboratory specializing in surveillance studies and clinical trials, key milestones along the continuum from drug development to commercialization. IHMA utilizes state of the art technology, leading to first-class testing and data as well as sound economic frameworks. IHMA's services can be customized to best align with its clients' unique testing needs. This ensures successful drug development, commercialization, and post-marketing pathways.
For more information, visit the IHMA website at: www.ihma.com
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
Mash Group Oyj22.6.2018 12:37 | pressemeddelelse
Mash named as one of the Fintech 50
Graduate Management Admission Council22.6.2018 06:02 | pressemeddelelse
GMAC Launches 'Study in China' Initiative in Partnership with 11 Leading Business Schools in China
Shyft Network21.6.2018 20:20 | pressemeddelelse
Shyft Unveils Board of Advisors Comprised of Top Crypto, Industry, and Regulatory Leaders United to Redefine Identity, Regulatory Compliance and Privacy For All
VITEC21.6.2018 19:02 | pressemeddelelse
United Shore Selects VITEC's EZ TV IPTV & Digital Signage Platform for New Headquarters
SEMAFO Inc.21.6.2018 17:25 | pressemeddelelse
SEMAFO Announces Retirement of VP, Exploration & Mine Geology; Announces Geology Team Succession
Bombardier Transportation20.6.2018 11:54 | pressemeddelelse
Bombardier's Chinese Joint Venture Wins Contract to Provide an INNOVIA Automated People Mover System to Shenzhen Airport
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum